BiotechTube

PRGN-3006 T Cells

Phase 1Active
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia

Conditions

Acute Myeloid Leukemia, Myelodysplastic Syndromes

Trial Timeline

May 20, 2019 → Aug 1, 2025

NCT ID
NCT03927261

About PRGN-3006 T Cells

PRGN-3006 T Cells is a phase 1 stage product being developed by Precigen for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT03927261. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndromes.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03927261Phase 1Active

Competing Products

20 competing products in Acute Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77
YH14659 + clopidogrel & aspirinYuhanPhase 1
33

Other Products from Precigen

Zopapogene imadenovec (Zopa)Approved
80
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePhase 2
47
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePhase 1/2
36
INXN-4001Phase 1
28